147 related articles for article (PubMed ID: 32687015)
1. Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report.
Funada M; Nawata M; Nawata A; Miyamoto T; Saito K; Tanaka Y
Mod Rheumatol Case Rep; 2021 Jan; 5(1):11-15. PubMed ID: 32687015
[TBL] [Abstract][Full Text] [Related]
2. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
[TBL] [Abstract][Full Text] [Related]
3. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol: in rheumatoid arthritis.
Duggan ST; Keam SJ
BioDrugs; 2009; 23(6):407-17. PubMed ID: 19894782
[TBL] [Abstract][Full Text] [Related]
5. Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature.
Koda K; Toyoshima M; Nozue T; Suda T
Intern Med; 2020 Aug; 59(16):2015-2021. PubMed ID: 32389943
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
Punzi L; Lapadula G; Mathieu A
BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
[TBL] [Abstract][Full Text] [Related]
7. A rheumatoid arthritis patient with delivery who started certolizumab pegol and tacrolimus during pregnancy.
Ito S; Ishikawa H; Kato R
Mod Rheumatol Case Rep; 2022 Jan; 6(1):6-9. PubMed ID: 34477867
[TBL] [Abstract][Full Text] [Related]
8. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.
Stokes MB; Foster K; Markowitz GS; Ebrahimi F; Hines W; Kaufman D; Moore B; Wolde D; D'Agati VD
Nephrol Dial Transplant; 2005 Jul; 20(7):1400-6. PubMed ID: 15840673
[TBL] [Abstract][Full Text] [Related]
9. Certolizumab-induced lichenoid eruption in a patient with rheumatoid arthritis.
Kunadia A; Shulman K; Sami N
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34887290
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol was effective for treating residual synovitis after total knee arthroplasty in a patient with rheumatoid arthritis: therapeutic monitoring by ultrasound.
Kawashiri SY; Michitsuji T; Kawakami A
J Med Ultrason (2001); 2018 Apr; 45(2):371-374. PubMed ID: 28725981
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Gálvez Muñoz JG; Saiz Cuenca ES; Fry-Smith A
Cochrane Database Syst Rev; 2011 Feb; (2):CD007649. PubMed ID: 21328299
[TBL] [Abstract][Full Text] [Related]
13. Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report.
Horai Y; Ishikawa H; Iwanaga N; Izumi Y; Matsuoka Y; Miura S; Kawakami A
J Clin Pharm Ther; 2020 Oct; 45(5):1179-1182. PubMed ID: 31990069
[TBL] [Abstract][Full Text] [Related]
14. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Kynaston-Pearson FJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD007649. PubMed ID: 25231904
[TBL] [Abstract][Full Text] [Related]
15. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
[TBL] [Abstract][Full Text] [Related]
17. Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study.
Saraux A; Combe B; Fagnani F; Cukierman G; Bru I; Joubert JM; Schuller JC; Massol J; Flipo RM
Clin Exp Rheumatol; 2021; 39(4):781-789. PubMed ID: 32896261
[TBL] [Abstract][Full Text] [Related]
18. Rapidly progressive glomerulonephritis with D-penicillamine.
Nanke Y; Akama H; Terai C; Kamatani N
Am J Med Sci; 2000 Dec; 320(6):398-402. PubMed ID: 11149553
[TBL] [Abstract][Full Text] [Related]
19. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy.
Simms R; Kipgen D; Dahill S; Marshall D; Rodger RS
Am J Kidney Dis; 2008 Mar; 51(3):e11-4. PubMed ID: 18295046
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.
Deeks ED
BioDrugs; 2016 Dec; 30(6):607-617. PubMed ID: 27704400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
